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http://www.biomedcentral.com/1471-2407/13/93RESEARCH ARTICLE Open AccessTransposon activation mutagenesis as a screening
tool for identifying resistance to cancer
therapeutics
Li Chen1,2*, Lynda Stuart2, Toshiro K Ohsumi3, Shawn Burgess4, Gaurav K Varshney4, Anahita Dastur1,
Mark Borowsky3, Cyril Benes1, Adam Lacy-Hulbert2 and Emmett V Schmidt2Abstract
Background: The development of resistance to chemotherapies represents a significant barrier to successful cancer
treatment. Resistance mechanisms are complex, can involve diverse and often unexpected cellular processes, and
can vary with both the underlying genetic lesion and the origin or type of tumor. For these reasons developing
experimental strategies that could be used to understand, identify and predict mechanisms of resistance in
different malignant cells would be a major advance.
Methods: Here we describe a gain-of-function forward genetic approach for identifying mechanisms of resistance.
This approach uses a modified piggyBac transposon to generate libraries of mutagenized cells, each containing
transposon insertions that randomly activate nearby gene expression. Genes of interest are identified using next-
gen high-throughput sequencing and barcode multiplexing is used to reduce experimental cost.
Results: Using this approach we successfully identify genes involved in paclitaxel resistance in a variety of cancer
cell lines, including the multidrug transporter ABCB1, a previously identified major paclitaxel resistance gene.
Analysis of co-occurring transposons integration sites in single cell clone allows for the identification of genes that
might act cooperatively to produce drug resistance a level of information not accessible using RNAi or ORF
expression screening approaches.
Conclusion: We have developed a powerful pipeline to systematically discover drug resistance in mammalian cells
in vitro. This cost-effective approach can be readily applied to different cell lines, to identify canonical or context
specific resistance mechanisms. Its ability to probe complex genetic context and non-coding genomic elements as
well as cooperative resistance events makes it a good complement to RNAi or ORF expression based screens.
Keywords: Transposon mutagenesis, Chemotherapy, Resistance, Gene activationBackground
The development of resistance to cancer therapeutics
represents a major hindrance to the successful pharma-
cological treatment and eradication of tumors in patients.
Although some progress has been made in combining or
augmenting treatments to counteract resistance, a major* Correspondence: lchen13@partners.org
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reproduction in any medium, provided the orobstacle is our limited understanding of the mechanisms
of resistance to current or novel therapeutics. Drug re-
sistance can be mediated by further genetic and/or epige-
netic changes in the tumor and, with the advent of high
throughput sequencing, it is now feasible to systematically
survey mutations in tumor genomes from patients follo-
wing resistance development. However, the identification
of the relevant ‘driver’ mutations, and other potential tar-
gets in resistance pathways, remains challenging.
A complementary approach is to identify resistance
pathways experimentally using in vitro culture or animal
model systems. Findings from such studies can then be
used to inform analysis of patient samples and developtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identification of resistance genes has focused largely on
reverse genetic and chemical biology approaches, includ-
ing cDNA and RNAi library screens [1,2] or combined
small molecule inhibitor and siRNA screens [3]. Such
approaches can require expensive reagents and specia-
lized platforms, and the need to consistently deliver
siRNAs limits their applicability. Perhaps more import-
antly, as reverse genetic approaches, they are biased to-
ward previously characterized genetic elements.
Forward genetic approaches using mobile genetic ele-
ments provide a powerful alternative method for gene
discovery that can overcome many of the limitations of
reverse genetic approaches. Mutagenesis with mobile
genetic elements that insert into the genome offers a
great scope for screening as these provide readily detec-
ted tags to identify insertion sites, and can potentially ei-
ther activate or disrupt gene expression. Retroviruses
have been used for insertional mutagenesis to identify
oncogenes and study therapeutic resistance in tumors
[4-6], however they preferentially insert in regions of
open chromatin and high gene expression, leading to po-
tential bias in results from genome-wide screens. Fur-
thermore, the requirements for viral long terminal
repeats (LTRs) and other structural restrictions limit the
use of complex DNA constructs, limiting its applications
to loss-of-function mutagenesis [7] and specialized hap-
loid cell lines [8].
Transposons, another class of mobile genetic elements
[9], have increasingly been utilized as genetic tools in
mammals after the discovery and engineering of two
transposons, Sleeping Beauty (SB) and piggyBac (PB)
[10-13]. A major advantage of transposons is the simpli-
city of their integration machinery, which permits the
incorporation of long DNA sequences, including func-
tional genetic elements such as promoters, transcrip-
tional stops and splicing sequences. This flexibility has
allowed development of a variety of powerful muta-
genesis schemes [14,15]. In their simplest application,
transposons disrupt genes leading to loss of function,
logically analogous to RNAi screens. With the incorpor-
ation of splice acceptors and reporter genes, transposons
can also be used as an alternative to retroviral gene-
traps [16,17]. Such gene disruption approaches are the
basis for genome-wide insertion libraries in mouse em-
bryonic stem cells [14,18]. Alternatively, inclusion of
functional promoters within the transposon creates “ac-
tivation tags” that cause expression of genes in which
they land [19]. Activation tagging has been used in
mouse somatic models to identify oncogenes [20,21].
This approach has great potential for gene discovery as
it combines the strong phenotype of ‘gain-of-function’
approaches with the ability to probe the entire genome,
including novel or uncharacterized genes and transcripts.Here we report the development of transposon-based
gene activation tagging for discovery of chemotherapeu-
tic resistance genes. We constructed an activation PB
transposon, generated mutagenesis libraries from several
cancer cell lines, and characterized the mutations by
sample barcoding and high-throughput sequencing. We
validated this system by screening for genes involved in
resistance to the microtubule targeting drug paclitaxel
and identifying the multidrug resistance (MDR) gene
ABCB1 as the primary gene target. Through further ana-
lysis of individual paclitaxel resistant clones, we also
identify potential modifiers of ABCB1-mediated resist-
ance. Hence, this study establishes a robust, flexible and
adaptable system for identifying drug resistance.
Methods
Plasmid construction
Transposon plasmid PB-SB-PGK-neo-bpA and trans-
posase plasmid pCMV-PBase were obtained from Pentao
Liu of the Wellcome Trust Sanger Institute. This plas-
mid was designed as an insertion mutagen that dis-
rupted the structure of the inserted host gene. Several
changes were made in PB-SB-PGK-neo-bpA to convert
it to an activating mutagen. The plasmid is first digested
with HindIII restriction enzyme and calf intestinal phos-
phatase, and ligated with a PCR-amplified fragment con-
taining the CMV enhancer and promoter sequence [22]
and the splice donor from the rabbit beta-globin intron
[23] to make pPB-SB-CMV-neo-SD. The pPB-SB-CMV-
neo-SD plasmid was then digested with BglII and XmaI
to remove the PGK-Neo-bpA cassette, and was ligated
with a PCR-amplified SV40-driven puromycin cassette
to provide a rapid selection marker to identify successful
integrants. The final plasmid was sequence-verified and
named pPB-SB-CMV-puro-SD.
Cell line transfection for library construction
To make a library, 1 × 107 cells were plated overnight
in four T175 flasks at cell density of 1 × 105 cells per ml.
HeLa and MCF7 were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with glutaMAX
(Invitrogen) and 10% fetal bovine serum (FBS). T47D
was cultured in RPMI with glutaMAX and 10% FBS.
IMR32 was cultured in Eagle’s Minimum Essential
Medium (EMEM) supplemented with 10% FBS. Cells
were co-transfected with 36 μg pPB-SB-CMV-puro-SD
and 36 μg pCMV-PBase plasmids using 216 μl Fugene 6
(Roche) and 4.5 ml serum-free OPTI-MEM. After three
days, cells were treated with fresh media with 2 μg/ml
puromycin and cultured for additional 7–10 days. Cells
surviving antibiotics treatment were harvested and
cryopreserved as transposon-tagged prescreened librar-
ies. In total, eight independent libraries were cons-
tructed, two for each cell line. To measure the insertion
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HeLa library were diluted and plated in a 96-well plate
at average one cell per well. Five single cell colonies were
identified, expanded and harvested for analysis.
Transposition efficiency
To determine transposition efficiency, cells were trans-
fected as above. One day after transfection, one cell plate
was trypsinized and re-plated to a 6-well plate at various
dilution ratios. Cells were treated with puromycin three
days after transfection until colonies could be stained
with Methylene Blue for visual counting. Transposition
efficiency was defined as the proportion of initially seeded
cells that could form puromycin-selected colonies.
Paclitaxel screen
One million transposon-tagged cells from each library
were plated in 100 mm tissue culture plates for drug
treatment. Native untagged cells were similarly plated as
study control. Paclitaxel dosages were 20 ng/ml for HeLa
and MCF7, 15 ng/ml for T47D and 4 ng/ml for IMR32.
Dosages were chosen as to sufficiently kill all parental
cells within one week. Cells were treated until paclitaxel-
resistant colonies were visible. Treatment time varied
among cell lines depending on proliferation rates, and
usually took ten days up to two weeks. Cells were then
either harvested as resistant clones, or as resistant pools.
To isolate resistant clones, colonies were picked from
the drug-treated plates using 3 mm diameter cloning
discs (Sigma), and expanded in 6-well plates in the pres-
ence of puromycin and paclitaxel. Cell clones exhibited
stable resistance to both paclitaxel and puromycin, con-
tinuing to grow when retreated after 2 weeks culture in
the absence of either agent. To harvest resistant pools,
cells from the paclitaxel-treated plates were trypsinized
and replated in the presence of puromycin and pacli-
taxel for one more week to remove any remaining non-
resistant cells. These screens were performed on all eight
libraries, including replicate screens for one library of each
cell line.
Splinkerette PCR and nextgen sequencing for insertion
site detection
Genomic DNA was harvested from samples using
DNeasy Blood & tissue Kit (Qiagen). Insertion sites can
be detected by splinkerette PCR, a modified version of
ligation-mediated PCR [24]. For the HeLa prescreened
library, 3.3 μg genomic DNA was digested with 10 units
of Csp6I (Fermentas) at 37°C for two hours, and ligated
to 100 picomole double-stranded linker catalyzed by
2000 units of T4 DNA ligase at 16°C for overnight. The
ligated sample was amplified with primers LP1 and
PB51-IL in a 100 μl PCR reaction. Primer LP1 matches
the linker sequences, and primer PB51-IL matches thetransposon sequences. The thermo-cycling condition is
the following: 3 min/94°C, 10 cycles of 15 sec/94°C; 30
sec/72°C with −1°C touchdown/cycle; 1 min/72°C, 20
cycles of 15 sec/94°C; 30 sec/62°C; 1 min/72°C, and 20
min/72°C. One microliter of the first PCR product was
re-amplified in a 50 μl PCR using nested primers LP2a
and PB52-ILa that contain Illumina single-end reaction
adapter sequences for binding to the flowcell. Thermo-
cycling condition was similar to that of the first PCR
with 10 touchdown cycles and 10 regular cycles. Ampli-
fied products were purified using QIAquick PCR Purifi-
cation Kit (Qiagen). For paclitaxel resistant pools and
clones, 170ng genomic DNA was digested with 2 units
of Csp6I and ligated to 10 picomole linkers. Up to 96
samples were processed with barcode linkers in a multi-
well plate. Samples were pooled after PCR and purified.
Sequencing was performed using Illumina HiSeq 50 Sin-
gle Read following standard protocols except that sample
loading density was reduced by 50% to avoid over-
clustering due to the first 10 repetitive nucleotides. Each
multiplexed cohort is loaded in one lane of the flow cell.
Custom sequencing primer Seq-P1 matches the linker
sequences prior to the barcodes and the read direction is
opposite to CMV (Additional file 1: Table S1). Sequen-
cing data were de-multiplexed and trimmed to remove
the barcode plus 1 adjacent base remaining from ligation
at the Csp6I half site, and any library adapter sequence
present at the 3’ end of each read was removed. Reads of
7 bp or longer were retained and aligned to the hg19
reference genome using Bowtie alignment program [25],
keeping only unique alignments placing the 5’ end of
a trimmed read within 3 bp of a Csp6I site. All fur-
ther analysis performed on the read counts at each
Csp6I site.TOPO cloning and sanger sequencing
Nested PCR products of resistant clones (7 from MCF7,
1 from HeLa, and 4 from T47D) were prepared as above
and cloned into vector pCR2.1-TOPO (Invitrogen). Bac-
terial colonies were sequenced with primer PB5-ILseq
(Additional file 1: Table S1) from the transposon side.
Insertion sites were aligned using the BLAT function of
the UCSC Genome Browser version hg19 (http://genome.
ucsc.edu/cgi-bin/hgGateway).Quantitation of mRNA expression
Total RNA was isolated using Qiagen RNeasy Mini kit.
One microgram of total RNA was treated with RNase-
free DNase to remove genomic DNA. First-strand cDNA
was synthesized using Roche Transcriptor First Strand
cDNA Synthesis kit, and quantitated by BIO-RAD SYBR
Green. All reactions were normalized to actin.
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To detect the chimeric mRNA, mRNA was reverse-
transcribed as above. 1 μl cDNA was PCR-amplified
using a forward primer specific to the PB transposon se-
quence and the reverse primer matching the ABCB1
exon 3 sequence. The thermo-cycling conditions are:
3min/94°C, 30 cycles of 30 sec/94°C; 30 sec/55°C; 30
sec/72°C, and 5min/72°C. PCR products were frac-
tionated on 1.7% agarose gel. The control PCR used the
primer pair provided in the cDNA synthesis kit to amp-
lify the housekeeping gene hPBGD for 35 cycles with
50°C annealing temperature, and the PCR products were
fractionated on a 3% gel.
Paclitaxel sensitivity assays
IMR32 Cells were reverse-transfected in a 96-well plate
with either a control pCMV plasmid or pCMV6-ABCB1
plasmid (Origene). Each well contained 100 ng plasmid
DNA, 0.3 μl Fugene 6 transfection reagent, and 10 μl
OPTI-MEM, and 10,000 IMR32 cells in 100 μl antibio-
tics-free complete EMEM were seeded to each well.
After two days, medium was replenished and cells were
treated with serial-diluted paclitaxel for five days. Each
sample was assayed with four replicate wells. Viability
was measured by CellTiter-Glo (Promega) and data were
processed using GraphPad Prism. Error bars represented
standard error of means (SEM, n=4).
Western blot
IMR32 cells were transfected with a control pCMV plas-
mid or pCMV6-ABCB1 plasmid respectively. Transfec-
tion was performed in a 6-well plate with each well
containing 2 μg plasmid DNA, 6 μl Fugene 6 transfection
reagent, 100 μl OPTI-MEM, and 200,000 IMR32 cells in
2 ml EMEM. After three days, cell were lysed with NP40
cell lysis buffer (Invitrogen) and sonicated to shear ge-
nomic DNA. Samples were diluted in SDS sample loa-
ding buffer, fractionated by SDS-PAGE (Bio-Rad), and
transferred to polyvinylidene difluoride membrane. The
membrane was blotted with MDR1/ABCB1 rabbit po-
lyclonal antibody (Cell Signaling Technology #12273)
diluted by 2,500-fold, and goat anti-rabbit IgG (Thermo
Scientific #31460) diluted by 10,000-fold. For actin
controls, the membrane was blotted with anti-actin rab-
bit monoclonal antibody diluted by 2,500-fold (Cell Sig-
naling Technology #4970) and goat anti-rabbit IgG by
10,000-fold. Images were captured by G:Box (Syngene).
Statistical and bioinformatics methods
To identify potential insertion sites in analysis of resist-
ant pools and clones, we first filtered sequencing data to
exclude ‘background’ signal derived from contaminating
non-resistant cells or the low incidence of PCR products
from inappropriate linker reactions or PCR reactions.We assumed that such background signal would follow
a Poisson distribution. This was supported by our obser-
vation that a frequency distribution of sequence analysis
from resistant cells followed a bi-phasic distribution,
with a large number of different sequences represented
at low frequency (1–50 reads) which resembled a
Poisson distribution, combined with a series distinct
sequences present at high frequency (100 reads up-
wards). We selected sequences present at >100 reads for
further analysis, which we estimate represents significant
enrichment (p < 0.05) over background signal. For ana-
lysis of pools of resistant cells insertion sites and
targeted genes were then compiled between all samples,
removing any insertions seen twice in repeated analysis
of the same sample. For analysis of sequences from re-
sistant clones, samples were further filtered to identify
the 1–10 sequences present at highest frequency in each
clone, based on our previous analysis of the likely num-
ber of transposon insertions per cell. Clones were then
clustered manually based on shared insertion sites, and
any samples clearly derived from more than one clone
excluded. Data were then visualized using Gene Pattern
software (Broad Institute of MIT and Harvard).
We use the Database for Annotation, Visualization
and Integrated Discovery (DAVID) tool to perform func-
tional analysis on genes enriched in the resistant pools
(http://david.abcc.ncifcrf.gov). Only candidate genes
identified above were used for analysis. Enriched genes
were both listed as clusters and as an annotation chart.
To estimate the number of insertions needed to cover
the genome, we assumed that only forward strand in-
sertions within 64kb upstream could activate a gene
based on our observation. We further postulated that
the random event of integration within this 64kb region
followed Poisson distribution. To achieve at least 1 in-
sertion in 95% of total genes, the expected mean occur-
rence needed to be 3.0 [P (3.0, ≤0) = 0.05], which
translated to 21.3kb gap between two insertions. Assum-
ing genome size of 3 × 106 kb, 1× genome coverage
would need 2.8 × 105 insertions. To achieve 2× coverage,
the expected mean would be 4.75 [P (4.75, ≤1) = 0.05],
equivalent to 4.4× 105 insertions.
Results
Construction of gene activating transposons and
generation of libraries of mutant cells
Classic transposons consist of two functional compo-
nents: a pair of short terminal repeats that target the
host genome, and a transcribed transposase enzyme that
catalyzes integration/ excision. Packaging these two ele-
ments separately allows experimental manipulation of
transposons. The dual function transposon plasmid PB-
SB-PGK-neo-bpA [26] that we obtained contains piggy
Bac/ Sleeping Beauty (PB/SB) terminal repeats for both
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moter-driven neomycin selection marker for selection
but lacks other transcription elements to activate host
genes. Integration of this plasmid therefore can only dis-
rupt the structure and expression of the host gene. To
convert this plasmid to an activator mutagen, we added
the cytomegalovirus (CMV) enhancer and promoter se-
quence, and a splice donor sequence, between the PB/SB
inverted repeats (Figure 1A). The CMV enhancer and
promoter contained a canonical TATA box and a strong
upstream activation sequence that together can initiate
strong transcription. The splice donor is able to combine
with host splice acceptor downstream of the insertion
site to generate a functional chimeric RNA. This gene-
rated a new transposon designed to have long range acti-
vation effects on gene expression when inserted in the
forward orientation 5’ of the first coding exon. Further-
more, the transposon may also cause less predictable
and short-range effects when inserted in the reverse dir-
ection or intragenically. Although the SB repeats were
left intact, we only chose to use the PB to generate
mutated libraries in a range of human cell lines, due
to its higher efficiency and lower insertion site bias
compared with SB [13,26]. Cells were co-transfected
with PB transposon and transposase plasmids, and se-
lected for puromycin resistance (Figure 1B). When co-
transfected with transposase, transposons were stably
integrated into cells at a frequency of between 6.3 and
0.3% of the starting population of cells (Figure 1C),
whereas no integration was seen when transposons were
transfected alone. The transposition frequency observed
in HeLa cells was similar to that published by others
[13] and the lower frequency we saw in other cell lines
most likely reflects the relative efficiency of transfection
with the plasmids. We selected 4 cell lines, HeLa cer-
vical cancer cells, IMR32 neuroblastoma cells, MCF7
breast cancer cells and T47D breast cancer cells, for
generation of libraries. For each cell line we transfected
107 cells, generating libraries of 1–6 × 105 independent
elements. The insertion sites could be detected by splin-
kerette PCR and Illumina next generation sequencing
(Figure 1D). We then went on to generate transposon
mutagenized libraries; screen with a selection reagent;
detect the insertion sites in resistant samples; and finally
link the insertion events (genotype) to the resistance
(phenotype) (Figure 1E).
Characterization of insertion libraries
To determine the extent of genomic distribution in our
PB transposon libraries and provide a reference to sub-
sequent chemotherapy resistant samples, insertion sites
from a HeLa cell library were analyzed using Illumina
next generation sequencing (Figure 2A). 4.6 × 105 uni-
que insertion sites were identified corresponding to 2.4%of all 19,228,691 TTAA integration sequences in the
hg19 human genome. Insertion sites were characterized
for their distribution throughout the genome and prox-
imity to genes (Additional file 2: Dataset S1). This
indicated widespread coverage of insertions throughout
the genome, without any clear ‘hotspots’. Mean distance
between insertion sites was 6.7kb, and 99.5% of gaps bet-
ween insertions were of less than 44.5 kb. Few insertions
were seen in the structural DNA of centromeres, or in
the short arms of some chromosomes. This is expected
due to the presence of heterochromatin and highly re-
petitive sequences that reduce insertions and confound
analysis of any insertions that could occur. As very few
annotated genes are located in these regions, the impact
of the effective lack of insertions in these regions on
functional mutagenesis is likely to be minimal.
Although a previous smaller study reported a pre-
ference of PB for transcribed genes with 70 out of 104
insertions being intragenic [13], our study found that
just 45.6% of total insertion sites were located within
transcribed gene sequences. This observation was con-
sistent with the fact that 40.8% of all TTAA sequences
in the genome are intragenic, indicating that there was
no major preference for the transposon to insert into
transcribed sequences. In addition, particularly relevant
for our gene activation strategy, given that our data
(described below) indicate that the transposon can, at
least in some instances, activate expression of genes at a
range of up to 64kb, we found 63% of insertions were
within 25kb of at least one gene, an arbitrary range we
chose to assign genes to insertion sites. Furthermore, we
found that the proportions of sense- versus antisense-
strand insertions are equivalent, both for the 63%
insertions and for all insertions, indicating that trans-
cribed sequences did not affect insert orientations.
To gain comprehensive identification of insertions
within individual cells, 5 clones from the Hela prescre-
ened library were isolated and sequenced, using DNA
barcoding (Figure 1D and Additional file 1: Table S1) to
permit multiplexing of samples. We found that each col-
ony contained between 1 and 11 insertions, with an
average of 6 insertions (Figure 2B). Based on this result,
we estimate that there may be up to 3.8 × 106 genomic
insertion sites in our HeLa library of 6 × 105 independ-
ent clones. However, only a fraction of these insertions
were revealed by our Illumina sequencing of the library,
likely due to technical limitations of the amount of gen-
omic DNA used as input or the efficiency of the PCR
reactions.
The generation of cell clones also provided the oppor-
tunity to explore the effects of transposon insertion on
gene expression, which is the key to our functional mu-
tagenesis approach As illustrated by our analysis of
ABCB1 in the next section, ‘sense’ insertions upstream of
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expected. In one clone in which the transposon inserted
upstream of the gene in the reverse orientation, expres-
sion was also increased (Figure 2C ACADL). In contrast,
intragenic insertion of the transposon caused decreased
expression. Based on this characterization of individuallytargeted genes, we conclude that our ‘activation tagging’
approach will result in consistent strong stimulation of
gene expression when inserted in the forward orien-
tation upstream of genes, coupled with less predictable
repression of expression for reverse direction and/or in-
tragenic insertions.
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transposon functional mutagenesis approach
Paclitaxel (taxol) is a well-defined microtubule interfer-
ing reagent broadly used in current chemotherapeutic
regimens. Mechanism of resistance to paclitaxel includes
elevated efflux pumps that reduce intracellular drug ac-
cumulation. The four transposon mutagenized cell li-
braries described above were treated with concentrations
of paclitaxel sufficient to kill all the parental cells, and inall cases, paclitaxel-resistant clones emerged. Although
drug-induced resistance could occur in native cell lines,
we chose to initiate the screen with high dosages of
drug, and screened for a relatively short period of time
to prevent this effect. We found almost no surviving
cells from native cell lines screened in parallel. In trans-
poson treated cells being screened, colonies were usually
identifiable as early as the background sensitive cells
were cleared, indicating these resistant colonies were
Chen et al. BMC Cancer 2013, 13:93 Page 8 of 15
http://www.biomedcentral.com/1471-2407/13/93derived from genetically stable clones in the transposon
mutagenized libraries. Transposon insertion sites in pools
of resistant cells from each screen were then identified by
Illumina sequencing and linked with nearby genes or
other genomic features such as miRNAs (Additional file 3:
Dataset S2). Sequencing data were first filtered to iden-
tify reads significantly (p<0.05) enriched over backgroundB
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http://www.biomedcentral.com/1471-2407/13/93suggesting they are genuine transposon insertion sites
found in the resistant cells. Of these 1,060 could be
mapped to 916 different known genes or transcripts. Most
genes were associated with a single transposon insertion
across all the screens and probably represent ‘passenger’
mutations that are present in resistant cells but do not
contribute to resistance. Only 115 genes were associated
with multiple transposons, with 16 associated with 3 or
more independent insertions. We also saw considerable
agreement in genes between different cell lines, with
around half of the genes identified in IMR32, MCF7 or
T47D cells also identified in HeLa cells (Figure 3B).
Identification of ABCB1 as the benchmark resistant gene
in all cell lines validated the mutagenesis screen
Multidrug resistant gene MDR1/ABCB1 is a well-known
major contributor of resistance [27]. ABCB1 was the
only gene associated with multiple insertions (31 inde-
pendent insertions at 25 different TTAA sites) in all cell
lines tested. This enrichment was not seen in the paren-
tal libraries, but only after paclitaxel selection, clearly
indicating ABCB1 as a causal factor for paclitaxel resist-
ance (Figure 4A). Furthermore, after selection, insertions
were clustered upstream of the gene open reading frame
and most were oriented with CMV promoter and splice
donor in the same direction as the ABCB1 gene, as pre-
viously predicted to result in increased expression. To
confirm that this was the case, we identified individual
clones with insertions in ABCB1 from 3 different cell
lines and confirmed transposon insertions in 5 clones
(1 in HeLa, 3 in T47D, 1 in MCF7) both by Illumina
sequencing and by Sanger sequencing. For all of the
insertion sites tested, transposon insertion led to increa-
sed expression of ABCB1 mRNA (by 35- to 600-fold)
over the prescreened library as determined by qPCR
(Figure 4B). Of note, this included 1 clone (TP1) in
which the transposon was inserted 64kb upstream of the
open reading frame, indicating that ‘activation tagging’
can work at considerable distances and does not appear
to involve the endogenous gene promoter. The signifi-
cant enrichment for insertions at genomic position near
ABCB1 predicted (and for some confirmed) to lead to
increased expression therefore provides strong validation
of this screening method for finding relevant resistance
mechanisms. We further detected the presence of
chimeric mRNA which contained both the transposon
and ABCB1 gene sequences in clones with insertions in
the ABCB1 intron, but not in native cells (Figure 4C).
While several other genes were associated with mul-
tiple transposon insertions (Figure 3A), these genes were
represented at significantly lower levels than ABCB1
(with none having greater than 6 independent insertions)
and none were seen in all cell lines tested. To test
whether the screen approach can enrich cell processesand pathways related to paclitaxel resistance, the 115
genes with ≥2 insertions were analyzed by functional
and structural motifs using Database for Annotation,
Visualization and Integrated Discovery tool (DAVID)
(Additional file 4: Dataset S4) [28]. There was strong en-
richment for genes associated with microtubule compo-
nents and cytoskeletal rearrangement, which are known
paclitaxel targets (Figure 3C) [29-31]. Ion transport
channels were likewise enriched, consistent with reports
that ion channels utilize microfilaments for their func-
tion and are susceptible to paclitaxel, and that their ex-
pression can affect sensitivity to paclitaxel [32-38]. Thus,
taken together, these results show that our transposon
mutagenesis approach can readily identify major resist-
ance mechanisms and provide potential insight into the
biological processes targeted by the drug used to select
resistant cells.
Use of clonal analysis to reveal gene interactions
To complement the analysis on resistant pools, we also
isolated and sequenced cell colonies from a resistant
pool of IMR32 cells (Additional file 5: Dataset S3) to
gain a deeper understanding of the insertions that may
drive paclitaxel resistance for individual clones. 82
clones were isolated and sequenced. After sequence ana-
lysis, 7 were found to be derived from more than one
originating clone and were excluded from further ana-
lysis. The remaining 75 were used for clustering analysis.
Clustering analysis revealed that these clones appeared
to be derived from at least 14 distinct originating clones
(Figure 5A). 8 of these originating clones carried in-
sertions in ABCB1 (ABCB1+), including clones contai-
ning only ABCB1 insertions, suggesting that it alone is
able to drive resistance in the context of this cell line.
To confirm this, we overexpressed ABCB1 in IMR32
cells by cDNA plasmid transfection and demonstrated
increased resistance associated with ABCB1 overexpres-
sion (Figure 5B, C).
Furthermore, the second most common hit in our
pool analysis (Figure 3A), a transcription factor MEIS1,
was only selected in IMR32 cells, and in clonal analysis
was only seen in clones that also had insertions in
ABCB1, implicating a possible role for MEIS1 in modi-
fying ABCB1-mediated resistance, rather than inducing
resistance alone. Insertion site orientation and positions
of transposons suggested that enhanced resistance is
associated with down regulation of MEIS1 expression
(Figure 5D), although we were not able to directly verify
this using siRNA-mediated gene knockdown (data not
shown). Therefore, to look for independent evidence of
MEIS1 function within ABCB1 context, we turned to
our recently published database of drug sensitivity for a
panel of cancer cell lines [39] and the publicly available
Broad Institute Cancer Cell Line Encyclopedia (CCLE)
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http://www.biomedcentral.com/1471-2407/13/93microarray database [40]. Our drug sensitivity database
consists of 639 human cancer cell lines in combination
with 130 targeted therapy or cytotoxic drugs, assayed in
a 9-point 256-fold serial dilution setting. In total, 143
cell lines across diverse cancer types that have been as-
sayed for paclitaxel sensitivity in our database overlapped
with the CCLE cell line collection for gene expression,
and were analyzed for correlation between paclitaxel sen-
sitivity and expression of ABCB1 and MEIS1. As expected,there was a significant correlation between ABCB1 expres-
sion and paclitaxel sensitivity, but not between MEIS1 and
paclitaxel sensitivity (Figure 5E). Instead, a negative correl-
ation was observed between MEIS1 expression and pacli-
taxel sensitivity only in cell lines expressing high levels of
ABCB1, but not in ABCB1-low cells, as predicted by
clonal analysis. Although independent validation will be
required to confirm the role of MEIS1 these data suggest
that transposon activation mutagenesis and clonal analysis
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http://www.biomedcentral.com/1471-2407/13/93can be used to reveal interesting information such as pri-
mary resistant events and modifiers.
Discussion
Acquired resistance to chemotherapeutic drugs remains
a major hurdle to effective cancer treatment and eradi-
cation, and a better understanding of the genes and
pathways that contribute to this is needed. Our data dem-
onstrate that transposon mutagenesis provides a powerful,
adaptable and cost-effective forward genetic approach foridentifying resistance genes. The use of parallel screening
in four separate cell lines with replicate samples to identify
both common and cell-line restricted resistance gene can-
didates illustrates the potential of this system for gaining a
deeper and more comprehensive view of resistance across
the full spectrum of malignancy.
Transposon-based gene activation systems have a uni-
que combination of properties that make them ideal for
studies of tumor cell resistance. First, they are readily
applied to gain-of-function genetic screens, unlike the
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ches for mammalian genomes. This may be of particular
relevance in tumors, where gene activation or amplifica-
tion are common transforming events. The potential for
long-range transcriptional activation and the need to hit
only one allele of a gene in diploid cells provides higher
effective genome coverage than gene inactivation strat-
egies at comparable levels of mutagenesis. Furthermore,
the presence of multiple effective mutations in single
cells should allow for identification of ‘cooperating’ re-
sistance genes, as suggested by our analysis of the
ABCB1/MEIS1 interaction in resistant clones. A second
advantage is the potential to identify resistance events
occurring from changes in expression of uncharacterized
or poorly understood genetic elements such as long
intergenic non-coding (LINC) RNA or microRNAs. We
have identified resistant cells bearing insertions in
LINC-RNAs and unannotated transcripts and further in-
vestigation of these mutations could shed light on new
genetic elements. Third, this system is readily trans-
ferable to new cell lines, including cells derived from
patient samples, and libraries can be expanded and re-
generated simply by re-transfection with the transposase.
Hence transposon-based screens allow for the rapid gen-
eration of resistant clones to single drugs or combined
therapies in specific tumor cells, providing insights into
potential resistance mechanisms. These could then be
used to guide design of new drug combinations and
tailor treatments to particular tumor types.
Transposon-based screening has been used previously
to identify potential mechanisms of resistance to the
antibiotic puromycin and chemotherapeutic, vincristine
[41]. In those studies, transposon insertions were found
primarily in Abcb1a/b (both drugs) and the closely
related transporter Abcg2 (puromycin only), reinforcing
our findings that overexpression of ABCB1 represents a
major mechanism of drug resistance. However, add-
itional candidate genes were not identified; this may be
due to the absence of a splice donor in the transposon
used, limiting the ability of the inserted promoter to acti-
vate gene expression, the presence of only one transposon
per cell, or the relatively limited analysis of insertion
events using capillary sequencing of isolated cell clones
Based on our finding that the transposon used here
can exert a strong transcriptional activation effect at
64kb upstream from open reading frames, we estimate
(using Poisson distribution) that libraries consisting of
just 4.7 × 104 clones (2.8 × 105 insertions) or 7.3 × 104
clones (4.4 × 105 insertions) respectively could be poten-
tially capable of activating 95% of genes by delivering at
least one or multiple forward upstream insertions.
Therefore in the case of HeLa cells we have approached
meaningful close to genome-wide coverage for activation
events. This is supported by our results with ABCB1,from which it is clear that all of our libraries had
sufficient coverage to provide multiple insertions in a
single strong resistance gene. We deduced that the low
incidence of identification of other resistance genes
could therefore reflect real differences in the ‘potency’ of
individual genes to promote resistance, with only ABCB1
being sufficient while other events requiring additive
effects of multiple genes to yield resistance in the high
taxol concentration used here for selection. This is also
supported by a prior transposon screen [41 described
above] which identified only ABC-family transporters as
potential resistance genes. Support for this also comes
from our bioinformatics analysis, which revealed con-
cordance of gene function or pathways between can-
didate resistance genes, with a strong enrichment in
microtubule related biology previously linked to paclitaxel
resistance.
However, even considering these potential limitations,
our data identify new possible resistance genes and streng-
then the evidence for previously identified candidates. As
an example, clonal analysis of resistant cells strongly im-
plicate MEIS1 as a modifier of ABCB1-mediated resist-
ance, and this is further supported by our analysis of a
large panel of tumor cells. MEIS1 is a class A homeodo-
main protein that acts as a cofactor for homeobox (HOX)
proteins, and has been implicated as a critical downstream
target of oncogenic fusion proteins in leukemia [42-45].
Although high expression promotes leukemia cell proli-
feration, silencing of MEIS1 increases resistance to the
chemotherapeutic etoposide [46], in agreement with our
findings in IMR32 cells. Our clonal analysis of mutations
also reveal CXCR4, the receptor for the chemokine
CXCL12 (stromal derived growth factor 1, SDF-1), as a
potential resistance gene that functions independently of
ABCB1 (Figure 5A). Up-regulation of CXCR4 is associated
with increased metastasis and poor prognosis in various
forms of cancer, in part due to effects on cellular pheno-
type, and is associated with chemotherapeutic resistance
in numerous tumor models. For example, CXCR4 is
upregulated in gefitinib-resistant non-small cell lung can-
cer cells and promotes epithelial-mesenchymal transition
(EMT) and self-renewal activity [47]. Likewise, CD133+
glioblastoma cancer stem cells with increased resistance
to a range of chemotherapeutic agents, including paclita-
xel, express high levels of CXCR4 [48], and high surface
expression of this chemokine receptor is considered a
marker of cancer stem cells [49]. Of direct relevance to
our results, increased CXCR4 expression and CXCL12/
CXCR4 signaling promote tumor cell resistance to the
chemotherapeutic gemcitabine [50].
Other genes identified in our screen, such as ALK and
PDE4D, increase tumor cell growth and protect from
apoptosis, and may therefore promote resistance through
these mechanisms.
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in different cell lines, including the protocadherin
PCDH15 and neuroblastoma breakpoint family member
NBPF11 have not been implicated in tumor resistance,
but based on the examples described above, may also
have important roles.Conclusions
We have developed a transposon-mediated activation
mutagenesis and screen approach to systematically iden-
tify chemotherapy resistance. We demonstrated the fea-
sibility of using this approach by identifying genes and
pathways related to paclitaxel resistance. This system pro-
vided unbiased genome-wide coverage with sufficient
depth to reliably capture the most well characterized me-
chanism of resistance in all cell lines processed and gener-
ate many believable additional hits based on available
functional annotation. In addition to a dramatically lower
cost and higher efficiency over RNAi and cDNA libraries,
this approach does not require a priori knowledge of can-
didate genes, can survey untranscribed regions and can
generate stable resistant clones pertinent to specific cell
lines. Although further analysis will be required to dissect
candidate genes, our findings highlight the potential for
transposon-based functional genetics to aid in identifying
both novel resistance genes and gene combinations. These
may allow improved selection of chemotherapeutic drugs
for particular classes of tumors, or the characterization of
“resistance gene signatures” for new or ‘black box’ tar-
geted therapeutics, allowing development of combination
therapies to overcome potential resistance, and improve
the efficacy and duration of new cancer therapies.Additional files
Additional file 1: Table S1. Nucleotides used in the study. Listed are
oligonucleotides used as ligation linkers and PCR primers. Li-EN U and
Li-En D were annealed to generate barcoded splinkerette linkers with a
sticky end compatible to the Csp6I-generated end. First round PCR
primers were LP1 and PB51-IL, second round PCR primers were LP2a and
PB52-ILa, sequencing primers were SeqP1 and PB5-ILseq. Barcode linkers
were arranged as a 96-well plate.
Additional file 2: Dataset S1. Insertion sites of a HeLa prescreened
transposon library. Shown are all insertion sites identified by Illumina
sequencing. Genes within +/-25kb range of the insertion sites are
indicated plus orientation and positional information.
Additional file 3: Dataset S2. Insertions in genes identified in selected
pools of paclitaxel-resistant cells. The “AlignStats” table shows barcode
assignment for each sample, as well as number of reads, number of
aligned reads, and percentage of alignment. The “summed pools” table
shows the number of independent insertions, the total number of
sequencing reads and the average number of sequencing reads
associated with a single gene in each screen. For each cell line, 3
independent screens were performed, using 2 libraries (labeled 1 and 2),
with library 1 screened twice (1A and 1B) and library 2, once. To remove
any bias arising from rescreening of the same library twice, any duplicate
insertion sites identified in both screen 1A and 1B were removed, anddata for 1A and 1B screens show only independent insertion sites. These
data are represented as a bubble plot and Venn diagram in Figures 3A, B.
Additional file 4: Dataset S4. Analysis of gene candidates by Database
for Annotation, Visualization and Integrated Discovery (DAVID) tool.
Genes identified by screen were fed to DAVID analysis tool (http://david.
abcc.ncifcrf.gov/). Only candidate genes identified in at least two
incidences in the Dataset S2 were used for analysis. Enriched genes were
both listed as clusters and as an annotation chart.
Additional file 5: Dataset S3. Insertions in isolated paclitaxel-resistant
colonies from IMR32 cells. Table shows data for individual transposon
insertion sites, expressed as (number of sequencing reads for insertion
site/ total number of sequencing reads for colony) x 100. Data were
filtered to remove any sites represented at < 1% of total reads for a
colony. Data were then ordered based on transposon insertion sites.
Also indicated are genes associated with each transposon insertion site,
as well as the orientation of the insertion (‘sense’ indicates that the CMV
promoter in the transposon is oriented in the same direction as the gene
promoter) and position (upstream of first coding exon, within gene
coding sequence or downstream of poly-adenylation site). These data
are represented by the heat map in Figure 5A.
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